# Clinical Trials Data KIT - Document 75

# Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy

## Clinical Trial: https://clinicaltrials.gov/study/NCT01219452

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Children of both genders with established clinical and echocardiographic diagnosis of dilated cardiomyopathy whose parents accept to participate in the trail.\n\* They should have symptoms and /or signs of heart failure, despite optimized medical treatment.\n\* Ejection fraction of left ventricular should be less than 50%, but more than 20%.\n\nExclusion Criteria:\n\n\* associate coronary artery disease.\n\* any history or suspicion of a toxic , pharmacologic or deposit etiology.\n\* associated malignant or pre -malignant systemic disease.\n\* associated hematologic disorder.\n\* a history of sustained ventricular tachycardia or fibrillation.\n\* a history of syncope during the previous year, or with an active infectious disease or positive tests to viral disease.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "1 Year",  
"stdAges": [  
"CHILD"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention KIT gene mutations specifically as either an inclusion or exclusion criterion. Therefore, having a KIT gene mutation \*doesn't automatically disqualify\* a child from the trial.   
  
However, the child must still meet \*all\* other inclusion criteria and \*none\* of the exclusion criteria to be eligible. The presence of the KIT mutation might be relevant if it contributes to a condition that falls under one of the exclusion criteria (e.g., a hematologic disorder or a pre-malignant systemic disease). More information about the specific impact of the KIT mutation in this child would be needed to determine final eligibility.